Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673

INTRODUCTION: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks. METHODS:...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Pediatr Blood Cancer
Главные авторы: Smith, Malcolm A., Hampton, Oliver A., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Keir, Stephen T., Wu, Jianrong, Kurmasheva, Raushan T., Wheeler, David A., Houghton, Peter J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4456187/
https://ncbi.nlm.nih.gov/pubmed/25263539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25201
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы